menu
    • menu

    Find Voriconazole manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 8
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 137234-62-9, Vfend, (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol, Uk-109496, (+/-)-voriconazole, Voriconazole vfend
    Molecular Formula
    C16H14F3N5O
    Molecular Weight
    349.31  g/mol
    InChI Key
    BCEHBSKCWLPMDN-MGPLVRAMSA-N
    FDA UNII
    USG4B1CD29
    Voriconazole
    A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.
    Voriconazole is an Azole Antifungal. The mechanism of action of voriconazole is as a Cytochrome P450 3A4 Inhibitor, and Cytochrome P450 2C19 Inhibitor, and Cytochrome P450 2C9 Inhibitor.
    1 2D Structure

    Voriconazole

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
    2.1.2 InChI
    InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
    2.1.3 InChI Key
    BCEHBSKCWLPMDN-MGPLVRAMSA-N
    2.1.4 Canonical SMILES
    CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O
    2.1.5 Isomeric SMILES
    C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O
    2.2 Other Identifiers
    2.2.1 UNII
    USG4B1CD29
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Uk 109,496

    2. Uk 109496

    3. Uk-109,496

    4. Uk-109496

    5. Uk109,496

    6. Uk109496

    7. Vfend

    2.3.2 Depositor-Supplied Synonyms

    1. 137234-62-9

    2. Vfend

    3. (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol

    4. Uk-109496

    5. (+/-)-voriconazole

    6. Voriconazole Vfend

    7. Uk-109,496

    8. Uk 109496

    9. Voriconzole

    10. (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol

    11. Vcz

    12. Voriconazole, (+/-)-

    13. Chembl638

    14. Nsc-759888

    15. Jfu09i87tr

    16. Usg4b1cd29

    17. Cpd000466350

    18. (r-(r*,s*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1h-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol

    19. 4-pyrimidineethanol, Alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1h-1,2,4-triazol-1-ylmethyl)-, (alphar,betas)-

    20. Chebi:10023

    21. 173967-54-9

    22. Vrc

    23. Voriconazol

    24. Dsstox_cid_26485

    25. Dsstox_rid_81656

    26. Dsstox_gsid_46485

    27. (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-((1h)-1,2,4-triazol-1-yl)-butan-2-ol

    28. (alphar,betas)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1h-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol

    29. 4-pyrimidineethanol, Alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1h-1,2,4-triazol-1-ylmethyl)-, (r-(r*,s*))-

    30. Voriconazole Related Compound A

    31. 188416-29-7

    32. Voriconazolum

    33. Vorikonazole

    34. Voriconazole [usan:inn:ban]

    35. Drg-0301

    36. Smr000466350

    37. Cas-137234-62-9

    38. Vfend (tn)

    39. Vfend I.v.

    40. Unii-jfu09i87tr

    41. Pfizer

    42. Ncgc00164622-01

    43. Voriconazole Solution

    44. Voriconazole- Bio-x

    45. Voriconazole - Vfend

    46. (alphar,betas)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1h-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol

    47. Voriconazole In Combination With Mgcd290

    48. Voriconazole [mi]

    49. Voriconazole [inn]

    50. Voriconazole [jan]

    51. Unii-usg4b1cd29

    52. Voriconazole [usan]

    53. Voriconazole [vandf]

    54. Schembl36233

    55. Voriconazole [mart.]

    56. Mls000759464

    57. Mls001424082

    58. Mls006010028

    59. Voriconazole [usp-rs]

    60. Voriconazole [who-dd]

    61. Voriconazole [ema Epar]

    62. Dtxsid5046485

    63. Voriconazole (jp17/usp/inn)

    64. Zinc14864

    65. Amy8903

    66. Voriconazole, >=98% (hplc)

    67. Bcpp000019

    68. Dtxsid201019420

    69. Hms2051n09

    70. Hms3260m22

    71. Hms3713f12

    72. Pharmakon1600-01502346

    73. Voriconazole [orange Book]

    74. Voriconazole [ep Monograph]

    75. Tox21_112241

    76. Tox21_500150

    77. Voriconazole [usp Monograph]

    78. Voriconazole 2.0 Mg/ml In Methanol

    79. Ac-823

    80. Bdbm50333117

    81. Nsc759888

    82. S1442

    83. Akos005145705

    84. Tox21_112241_1

    85. Ccg-100941

    86. Cs-1227

    87. Db00582

    88. Hy-w337569

    89. Ks-1157

    90. Nc00191

    91. Nsc 759888

    92. Ncgc00164622-02

    93. Ncgc00164622-04

    94. Ncgc00164622-06

    95. Ncgc00260835-01

    96. Bv164532

    97. Hy-76200

    98. ( Inverted Exclamation Marka)-voriconazole

    99. Voriconazole Related Compound A Rs [usp]

    100. Cs-0448910

    101. Sw197571-2

    102. V0116

    103. C07622

    104. D00578

    105. Ab00639948-04

    106. Ab00639948-06

    107. Ab00639948_07

    108. Ab00639948_08

    109. Voriconazole Related Compound A [usp-rs]

    110. Voriconazole, Vetranal(tm), Analytical Standard

    111. 234v629

    112. A807215

    113. Q412236

    114. J-006986

    115. Voriconazole Related Compound A [usp Impurity]

    116. Z2616414875

    117. Voriconazole, European Pharmacopoeia (ep) Reference Standard

    118. Voriconazole, United States Pharmacopeia (usp) Reference Standard

    119. (2r,3s)-2,3-bis(2,4-difluorophenyl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol

    120. 2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) Butan-2-ol

    121. 4-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methylene]-1-oxo-1,3-thiazolidin-5-one

    122. Voriconazole, Pharmaceutical Secondary Standard: Certified Reference Material

    123. (.alpha.r,.beta.s)-a-(2,4-difluorophenyl)-5-fluoro-.beta.-methyl-.alpha.-(1h-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol

    124. (2r,3s)-2-(2,4-difluoro-phenyl)-3-(5-fluoro-pyrimidin-4-yl)-1-[1,2,4]triazol-1-yl-butan-2-ol

    125. (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1h-1,2,4-triazol-1-yl) Butan-2-ol

    126. (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1h-1,2,4-triazol-1-yl)-2-butanol

    127. (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol

    128. 2r,3s-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol-4-pyrimidineethanol, ?-(2,4-difluorophenyl)-5-fluoro-?-methyl-?-(1h-1,2,4-triazol-1-ylmethyl)-,?(?r,?s)-

    129. 4-pyrimidineethanol, .alpha.-(2,4-difluorophenyl)-5-fluoro-.beta.-methyl-.alpha.-(1h-1,2,4-triazol-1-ylmethyl)-, (.alpha.r,.beta.s)-rel-

    130. 4-pyrimidineethanol, A-(2,4-difluorophenyl)-5-fluoro-.beta.-methyl-.alpha.-(1h-1,2,4-triazol-1-ylmethyl)-, (.alpha.r,.beta.s)-

    131. 4-pyrimidineethanol, Alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1h-1,2,4-triazol-1-ylmethyl)-, (alphar,betas)-rel-

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 349.31 g/mol
    Molecular Formula C16H14F3N5O
    XLogP31.5
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count5
    Exact Mass349.11504457 g/mol
    Monoisotopic Mass349.11504457 g/mol
    Topological Polar Surface Area76.7 Ų
    Heavy Atom Count25
    Formal Charge0
    Complexity448
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 4  
    Drug NameVfend
    PubMed HealthVoriconazole (By mouth)
    Drug ClassesAntifungal
    Drug LabelVFEND (voriconazole), a triazole antifungal agent, is available as a lyophilized powder for solution for intravenous infusion, film-coated tablets for oral administration, and as a powder for oral suspension. The structural formula is:Voriconazole...
    Active IngredientVoriconazole
    Dosage FormTablet; Injectable; For suspension
    Routeinjection; oral; Iv (infusion); Oral; iv (infusion)
    Strength200mg/5ml; 200mg; 200mg/vial; 50mg
    Market StatusPrescription
    CompanyPfizer

    2 of 4  
    Drug NameVoriconazole
    PubMed HealthVoriconazole
    Drug ClassesAntifungal
    Drug LabelVFEND (voriconazole), a triazole antifungal agent, is available as a lyophilized powder for solution for intravenous infusion, film-coated tablets for oral administration, and as a powder for oral suspension. The structural formula is:Voriconazole...
    Active IngredientVoriconazole
    Dosage FormTablet; Injectable; For suspension
    RouteIv (infusion); Oral
    Strength200mg/5ml; 200mg; 200mg/vial; 50mg
    Market StatusPrescription
    CompanyMylan Pharms; Sandoz; Teva Pharms

    3 of 4  
    Drug NameVfend
    PubMed HealthVoriconazole (By mouth)
    Drug ClassesAntifungal
    Drug LabelVFEND (voriconazole), a triazole antifungal agent, is available as a lyophilized powder for solution for intravenous infusion, film-coated tablets for oral administration, and as a powder for oral suspension. The structural formula is:Voriconazole...
    Active IngredientVoriconazole
    Dosage FormTablet; Injectable; For suspension
    Routeinjection; oral; Iv (infusion); Oral; iv (infusion)
    Strength200mg/5ml; 200mg; 200mg/vial; 50mg
    Market StatusPrescription
    CompanyPfizer

    4 of 4  
    Drug NameVoriconazole
    PubMed HealthVoriconazole
    Drug ClassesAntifungal
    Drug LabelVFEND (voriconazole), a triazole antifungal agent, is available as a lyophilized powder for solution for intravenous infusion, film-coated tablets for oral administration, and as a powder for oral suspension. The structural formula is:Voriconazole...
    Active IngredientVoriconazole
    Dosage FormTablet; Injectable; For suspension
    RouteIv (infusion); Oral
    Strength200mg/5ml; 200mg; 200mg/vial; 50mg
    Market StatusPrescription
    CompanyMylan Pharms; Sandoz; Teva Pharms

    4.2 Drug Indication

    For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.

    FDA Label

    Voriconazole is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:

    - treatment of invasive aspergillosis;

    - treatment of candidaemia in non-neutropenic patients;

    - treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);

    - treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.

    Voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections.

    Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT)

    recipients.

    Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:

    - treatment of invasive aspergillosis;

    - treatment of in candidaemianon-neutropenic patients;

    - treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);

    - Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.

    Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.

    Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.

    Voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged two years and above as follows:

    - treatment of invasive aspergillosis;

    - treatment of candidaemia in non-neutropenic patients;

    - treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);

    - Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.

    Voriconazole Accord should be administered primarily to patients with progressive, possibly life-threatening infections.

    Treatment of candidaemia in non-neutropenic patients, Treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei), Treatment of invasive aspergillosis, Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Voriconazole is a fungistatic triazole antifungal used to treat infections by inhibiting fungal growth. It is known to cause hepatotoxic and photosensitivity reactions in some patients.

    5.2 MeSH Pharmacological Classification

    14-alpha Demethylase Inhibitors

    Compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived ANTIFUNGAL AGENTS act through this mechanism. (See all compounds classified as 14-alpha Demethylase Inhibitors.)

    Antifungal Agents

    Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)

    Cytochrome P-450 CYP3A Inhibitors

    Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inhibitors.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    VORICONAZOLE
    5.3.2 FDA UNII
    JFU09I87TR
    5.3.3 Pharmacological Classes
    Azoles [CS]; Cytochrome P450 2C19 Inhibitors [MoA]; Cytochrome P450 2C9 Inhibitors [MoA]; Cytochrome P450 3A4 Inhibitors [MoA]; Azole Antifungal [EPC]
    5.4 ATC Code

    J02AC03

    J02AC03

    J02AC03

    J02AC03

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    J - Antiinfectives for systemic use

    J02 - Antimycotics for systemic use

    J02A - Antimycotics for systemic use

    J02AC - Triazole and tetrazole derivatives

    J02AC03 - Voriconazole

    5.5 Absorption, Distribution and Excretion

    Absorption

    The oral bioavailability is estimated to be 96% in healthy adults. Population pharmacokinetic studies report a reduced bioavailability pediatric patients with a mean of 61.8% (range 44.664.5%) thought to be due to differences in first-pass metabolism or due to differences in diet. Of note, transplant patients also have reduced bioavailability but this is known to increase with time after transplantation and may be due in part to gastrointestinal upset from surgery and some transplant medications. Tmax is 1-2 hours with oral administration. When administered with a high-fat meal Cmax decreases by 34% and AUC by 24%. pH does not have an effect on absorption of voriconazole. Differences in Cmax and AUC have been observed between healthy adult males and females with Cmax increasing by 83% and AUC by 113% although this has not been observed to significantly impact medication safety profiles.

    Route of Elimination

    Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine.

    Volume of Distribution

    The estimated volume of distribution of voriconazole is 4.6 L/kg. Population pharmacokinetic studies estimate the median volume of distribution to be 77.6 L with the central compartment estimated at 1.07 L/kg Voriconazole is known to achieve therapeutic concentrations in many tissues including the brain, lungs, liver, spleen, kidneys, and heart.

    Clearance

    The clearance of voriconazole is estimated to be a mean of 5.25-7 L/h in healthy adults for the linear portion of the drug's kinetics.

    5.6 Metabolism/Metabolites

    Voriconazole undergoes extensive hepatic metabolism through cytochrome enzymes CYP2C9, CYP2C19, and CYP3A4. CYP2C19 mediates N-oxidation with an apparent Km of 14 M and an apparent Vmax of 0.22 nmol/min/nmol CYP2C19. Voriconazole N-oxide is the major circulating metabolite, accounting for 72% of radiolabeled metabolites found. CYP3A4 contributes to N-oxidation with a Km of 16 M and Vmax of 0.05 nmol/min/nmol CYP3A4 as well as 4-hydroxylation with a Km of 11 M and a Vmax of 0.10 nmol/min/nmol CYP3A4. CYP3A5 and CYP3A7 provide minor contributions to N-oxidation and 4-hydroxylation. The N-oxide and 4-hydroxylated metabolites undergo glucuronidation and are excreted through the urine with other minor glucuronidated metabolites.

    Voriconazole has known human metabolites that include Hydroxymethyl Voriconazole and Voriconazole N-Oxide.

    S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560

    5.7 Biological Half-Life

    Voriconazole follows non-linear kinetics and has a terminal half-life of elimination which is dose-dependent.

    5.8 Mechanism of Action

    Voriconazole is used to treat fungal infections caused by a variety of organisms but including _Aspergillus spp._ and _Candida spp_. Voriconazole is a triazole antifungal exhibiting fungistatic activity against fungal pathogens. Like other triazoles, voriconazole binds to 14-alpha sterol demethylase, also known as CYP51, and inhibits the demethylation of lanosterol as part of the ergosterol synthesis pathway in yeast and other fungi. The lack of sufficient ergosterol disrupts fungal cell membrane function and limits fungal cell growth. With fungal growth limited, the host's immune system is able to clear the invading organism.

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - TABLET;ORAL - 200MG

    USFDA APPLICATION NUMBER - 21266

    read-more

    DOSAGE - TABLET;ORAL - 50MG

    USFDA APPLICATION NUMBER - 21266

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Topical

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Parenteral

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Dry Powder Inhalation

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ANALYTICAL

    Upload your methods for free, ask us

    ABOUT THIS PAGE

    Looking for 137234-62-9 / Voriconazole API manufacturers, exporters & distributors?

    Voriconazole manufacturers, exporters & distributors 1

    94

    PharmaCompass offers a list of Voriconazole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Voriconazole manufacturer or Voriconazole supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Voriconazole manufacturer or Voriconazole supplier.

    API | Excipient name

    Voriconazole

    Synonyms

    137234-62-9, Vfend, (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol, Uk-109496, (+/-)-voriconazole, Voriconazole vfend

    Cas Number

    137234-62-9

    Unique Ingredient Identifier (UNII)

    USG4B1CD29

    About Voriconazole

    A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.

    VCZ Manufacturers

    A VCZ manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of VCZ, including repackagers and relabelers. The FDA regulates VCZ manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. VCZ API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of VCZ manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

    VCZ Suppliers

    A VCZ supplier is an individual or a company that provides VCZ active pharmaceutical ingredient (API) or VCZ finished formulations upon request. The VCZ suppliers may include VCZ API manufacturers, exporters, distributors and traders.

    click here to find a list of VCZ suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

    VCZ USDMF

    A VCZ DMF (Drug Master File) is a document detailing the whole manufacturing process of VCZ active pharmaceutical ingredient (API) in detail. Different forms of VCZ DMFs exist exist since differing nations have different regulations, such as VCZ USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A VCZ DMF submitted to regulatory agencies in the US is known as a USDMF. VCZ USDMF includes data on VCZ's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The VCZ USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of VCZ suppliers with USDMF on PharmaCompass.

    VCZ JDMF

    The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

    The VCZ Drug Master File in Japan (VCZ JDMF) empowers VCZ API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

    PMDA reviews the VCZ JDMF during the approval evaluation for pharmaceutical products. At the time of VCZ JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

    click here to find a list of VCZ suppliers with JDMF on PharmaCompass.

    VCZ KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a VCZ Drug Master File in Korea (VCZ KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of VCZ. The MFDS reviews the VCZ KDMF as part of the drug registration process and uses the information provided in the VCZ KDMF to evaluate the safety and efficacy of the drug.

    After submitting a VCZ KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their VCZ API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of VCZ suppliers with KDMF on PharmaCompass.

    VCZ CEP

    A VCZ CEP of the European Pharmacopoeia monograph is often referred to as a VCZ Certificate of Suitability (COS). The purpose of a VCZ CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of VCZ EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of VCZ to their clients by showing that a VCZ CEP has been issued for it. The manufacturer submits a VCZ CEP (COS) as part of the market authorization procedure, and it takes on the role of a VCZ CEP holder for the record. Additionally, the data presented in the VCZ CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the VCZ DMF.

    A VCZ CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. VCZ CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

    click here to find a list of VCZ suppliers with CEP (COS) on PharmaCompass.

    VCZ WC

    A VCZ written confirmation (VCZ WC) is an official document issued by a regulatory agency to a VCZ manufacturer, verifying that the manufacturing facility of a VCZ active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting VCZ APIs or VCZ finished pharmaceutical products to another nation, regulatory agencies frequently require a VCZ WC (written confirmation) as part of the regulatory process.

    click here to find a list of VCZ suppliers with Written Confirmation (WC) on PharmaCompass.

    VCZ NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing VCZ as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for VCZ API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture VCZ as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain VCZ and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a VCZ NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of VCZ suppliers with NDC on PharmaCompass.

    VCZ GMP

    VCZ Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of VCZ GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right VCZ GMP manufacturer or VCZ GMP API supplier for your needs.

    VCZ CoA

    A VCZ CoA (Certificate of Analysis) is a formal document that attests to VCZ's compliance with VCZ specifications and serves as a tool for batch-level quality control.

    VCZ CoA mostly includes findings from lab analyses of a specific batch. For each VCZ CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    VCZ may be tested according to a variety of international standards, such as European Pharmacopoeia (VCZ EP), VCZ JP (Japanese Pharmacopeia) and the US Pharmacopoeia (VCZ USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search